NeuroOne Medical Technologies Files 8-K

TL;DR

NEUR filed a routine 8-K, no major news.

AI Summary

NeuroOne Medical Technologies Corporation filed an 8-K on January 14, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a standard disclosure for NeuroOne Medical Technologies, indicating the submission of required financial statements and exhibits to the SEC.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for financial statements and exhibits, not indicating any new material risks or events.

Key Players & Entities

• NeuroOne Medical Technologies Corporation (company) — Registrant
• January 14, 2025 (date) — Date of Earliest Event Reported
• Delaware (jurisdiction) — State of incorporation
• Eden Prairie, MN (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar

Filing Documents

• ea0227550-8k_neuroone.htm (8-K) — 26KB
• ea022755001ex99-1_neuroone.htm (EX-99.1) — 3KB
• ex99-1_001.jpg (GRAPHIC) — 352KB
• ex99-1_002.jpg (GRAPHIC) — 216KB
• ex99-1_003.jpg (GRAPHIC) — 263KB
• ex99-1_004.jpg (GRAPHIC) — 229KB
• ex99-1_005.jpg (GRAPHIC) — 167KB
• ex99-1_006.jpg (GRAPHIC) — 250KB
• 0001213900-25-003166.txt ( ) — 2232KB
• nmtc-20250114.xsd (EX-101.SCH) — 3KB
• nmtc-20250114_lab.xml (EX-101.LAB) — 33KB
• nmtc-20250114_pre.xml (EX-101.PRE) — 22KB
• ea0227550-8k_neuroone_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 14, 2025, NeuroOne Medical Technologies Corporation (the "Company") published a Letter to Shareholders where President and Chief Executive Officer of the Company, Dave Rosa, discussed the Company's achievements, ongoing progress and strategy to create and deliver value (the "Letter"). A copy of the Letter is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and incorporated herein by reference. The Letter is also posted to the Company's website at https://nmtc1.com/investors. The information in this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company's submission of this Current Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. This Current Report and Exhibit 99.1 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Letter to Shareholders, dated January 14, 2025. 104 Cover Page Interactive Data File (embedded within Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: January 14, 2025 By: /s/ David Rosa David Rosa Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR